Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Viral triggers of multiple sclerosis.
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.
Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls.
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
XVI European Charcot Foundation lecture: nutrition and environment, can MS be prevented?
Mycophenolate mofetil in the treatment of multiple sclerosis: A preliminary report.
Positive results from Phase 3 CONFIRM clinical trial show efficacy and safety of oral BG-12 in multiple sclerosis
Mycophenolate mofetil therapy in the management of inflammatory bowel disease - A retrospective case series and review.
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
[Recommendations for a brief international cognitive assessment for multiple sclerosis].
Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
Seeing illness in art and medicine: a patient and printmaker collaboration.
TECFIDERA® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.
SMC Says Yes to Aubagio® (teriflunomide), a New Once Daily First-line Oral Treatment Available for People with an Active Relapsing Remitting Form of MS
Scientists probe strategies to repair neuron damage in multiple sclerosis.
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
BIIB033 single ascending dose study in healthy volunteer subjects
Gender as risk factor for autoimmune diseases.
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells.
Recruiting women smokers: the engineering of consent.
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.
Improving the translational hit of experimental treatments in multiple sclerosis.
Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis.

Pages